CP Capital Limited: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: September 5, 2025, 3:56 pm

Quick Insight

Career Point Ltd, with a current share price of 376 and a market capitalization of 684 crore, boasts a reasonable P/E ratio of 11.4 and solid return metrics with ROE at 10.8% and ROCE at 13.4%. The company's high operating profit margin of 64% is noteworthy, reflecting operational efficiency. With promoters holding a significant stake of 63.68% and healthy reserves of 543 crore, Career Point appears to have a strong financial foundation. However, the low P/BV ratio of 0.96x may indicate undervaluation, presenting a potential opportunity for investors. Overall, Career Point's financial performance and ownership structure suggest a stable and promising investment option in the education industry.

Competitors of CP Capital Limited

All Competitor Stocks of CP Capital Limited

Quarterly Result

Last Updated: February 28, 2025, 8:27 pm

Below is a detailed analysis of the quarterly data for CP Capital Limited based on the most recent figures (Dec 2024) and their trends compared to the previous period:

• For Sales, as of Dec 2024, the value is 27.00 Cr.. The value appears strong and on an upward trend. It has increased from 26.00 Cr. (Sep 2024) to 27.00 Cr., marking an increase of 1.00 Cr..
• For Expenses, as of Dec 2024, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 10.00 Cr..
• For Operating Profit, as of Dec 2024, the value is 17.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Sep 2024) to 17.00 Cr., marking an increase of 1.00 Cr..
• For OPM %, as of Dec 2024, the value is 64.00%. The value appears strong and on an upward trend. It has increased from 62.00% (Sep 2024) to 64.00%, marking an increase of 2.00%.
• For Other Income, as of Dec 2024, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Sep 2024) to 1.00 Cr., marking a decrease of 1.00 Cr..
• For Interest, as of Dec 2024, the value is 0.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.00 Cr. (Sep 2024) to 0.00 Cr., marking a decrease of 1.00 Cr..
• For Depreciation, as of Dec 2024, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 1.00 Cr..
• For Profit before tax, as of Dec 2024, the value is 16.00 Cr.. The value appears to be declining and may need further review. It has decreased from 17.00 Cr. (Sep 2024) to 16.00 Cr., marking a decrease of 1.00 Cr..
• For Tax %, as of Dec 2024, the value is 19.00%. The value appears to be improving (decreasing) as expected. It has decreased from 25.00% (Sep 2024) to 19.00%, marking a decrease of 6.00%.
• For Net Profit, as of Dec 2024, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 13.00 Cr..
• For EPS in Rs, as of Dec 2024, the value is 7.29. The value appears strong and on an upward trend. It has increased from 7.10 (Sep 2024) to 7.29, marking an increase of 0.19.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 22, 2025, 5:32 pm

Growth

Last Updated: September 5, 2025, 1:35 am

Cash Flow

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for CP Capital Limited, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 20.95. This value is within the healthy range. It has decreased from 31.37 (Mar 24) to 20.95, marking a decrease of 10.42.
• For Diluted EPS (Rs.), as of Mar 25, the value is 20.95. This value is within the healthy range. It has decreased from 31.37 (Mar 24) to 20.95, marking a decrease of 10.42.
• For Cash EPS (Rs.), as of Mar 25, the value is 22.23. This value is within the healthy range. It has decreased from 33.52 (Mar 24) to 22.23, marking a decrease of 11.29.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 299.94. It has increased from 292.36 (Mar 24) to 299.94, marking an increase of 7.58.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 299.94. It has increased from 292.36 (Mar 24) to 299.94, marking an increase of 7.58.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 31.13. It has decreased from 55.84 (Mar 24) to 31.13, marking a decrease of 24.71.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 32.04. This value is within the healthy range. It has decreased from 43.24 (Mar 24) to 32.04, marking a decrease of 11.20.
• For PBIT / Share (Rs.), as of Mar 25, the value is 30.49. This value is within the healthy range. It has decreased from 41.07 (Mar 24) to 30.49, marking a decrease of 10.58.
• For PBT / Share (Rs.), as of Mar 25, the value is 28.18. This value is within the healthy range. It has decreased from 40.17 (Mar 24) to 28.18, marking a decrease of 11.99.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 20.67. This value is within the healthy range. It has decreased from 31.35 (Mar 24) to 20.67, marking a decrease of 10.68.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 20.95. This value is within the healthy range. It has decreased from 31.37 (Mar 24) to 20.95, marking a decrease of 10.42.
• For PBDIT Margin (%), as of Mar 25, the value is 102.93. This value is within the healthy range. It has increased from 77.44 (Mar 24) to 102.93, marking an increase of 25.49.
• For PBIT Margin (%), as of Mar 25, the value is 97.94. This value exceeds the healthy maximum of 20. It has increased from 73.56 (Mar 24) to 97.94, marking an increase of 24.38.
• For PBT Margin (%), as of Mar 25, the value is 90.52. This value is within the healthy range. It has increased from 71.94 (Mar 24) to 90.52, marking an increase of 18.58.
• For Net Profit Margin (%), as of Mar 25, the value is 66.40. This value exceeds the healthy maximum of 10. It has increased from 56.14 (Mar 24) to 66.40, marking an increase of 10.26.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 67.30. This value exceeds the healthy maximum of 20. It has increased from 56.17 (Mar 24) to 67.30, marking an increase of 11.13.
• For Return on Networth / Equity (%), as of Mar 25, the value is 6.98. This value is below the healthy minimum of 15. It has decreased from 10.73 (Mar 24) to 6.98, marking a decrease of 3.75.
• For Return on Capital Employeed (%), as of Mar 25, the value is 9.99. This value is below the healthy minimum of 10. It has decreased from 12.66 (Mar 24) to 9.99, marking a decrease of 2.67.
• For Return On Assets (%), as of Mar 25, the value is 6.10. This value is within the healthy range. It has decreased from 8.92 (Mar 24) to 6.10, marking a decrease of 2.82.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.01.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.07. This value is within the healthy range. It has increased from 0.06 (Mar 24) to 0.07, marking an increase of 0.01.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.08. It has decreased from 0.16 (Mar 24) to 0.08, marking a decrease of 0.08.
• For Current Ratio (X), as of Mar 25, the value is 2.41. This value is within the healthy range. It has decreased from 3.45 (Mar 24) to 2.41, marking a decrease of 1.04.
• For Quick Ratio (X), as of Mar 25, the value is 2.10. This value exceeds the healthy maximum of 2. It has decreased from 3.43 (Mar 24) to 2.10, marking a decrease of 1.33.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 4. It has decreased from 2.23 (Mar 24) to 0.00, marking a decrease of 2.23.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 9.56 (Mar 24) to 0.00, marking a decrease of 9.56.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 8.94 (Mar 24) to 0.00, marking a decrease of 8.94.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 90.44 (Mar 24) to 0.00, marking a decrease of 90.44.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 91.06 (Mar 24) to 0.00, marking a decrease of 91.06.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 13.87. This value is within the healthy range. It has decreased from 47.93 (Mar 24) to 13.87, marking a decrease of 34.06.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 9.95. This value is within the healthy range. It has decreased from 35.74 (Mar 24) to 9.95, marking a decrease of 25.79.
• For Enterprise Value (Cr.), as of Mar 25, the value is 796.39. It has increased from 541.28 (Mar 24) to 796.39, marking an increase of 255.11.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 14.06. This value exceeds the healthy maximum of 3. It has increased from 5.33 (Mar 24) to 14.06, marking an increase of 8.73.
• For EV / EBITDA (X), as of Mar 25, the value is 13.66. This value is within the healthy range. It has increased from 6.88 (Mar 24) to 13.66, marking an increase of 6.78.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 13.40. This value exceeds the healthy maximum of 3. It has increased from 5.05 (Mar 24) to 13.40, marking an increase of 8.35.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 90.43 (Mar 24) to 0.00, marking a decrease of 90.43.
• For Price / BV (X), as of Mar 25, the value is 1.39. This value is within the healthy range. It has increased from 0.96 (Mar 24) to 1.39, marking an increase of 0.43.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 13.40. This value exceeds the healthy maximum of 3. It has increased from 5.05 (Mar 24) to 13.40, marking an increase of 8.35.
• For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has decreased from 0.11 (Mar 24) to 0.05, marking a decrease of 0.06.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness